Before any clinical site is activated for patient enrollment, it must demonstrate full operational readiness during the Site Initiation Visit (SIV). A well-designed site readiness checklist serves as a critical quality assurance tool that enables Clinical Research Associates (CRAs), sponsors, and site staff to verify that all regulatory, logistical, and procedural components are in place. This tutorial provides a step-by-step approach to building and using site readiness checklists effectively to streamline trial startup and support audit preparedness.

Why a Site Readiness Checklist Is Essential

Without a structured checklist, critical steps may be missed, such as:

• Regulatory approvals not in place
• Untrained site staff handling study procedures
• Investigational product (IP) storage non-compliant with specifications
• Missing essential documents in the Investigator Site File (ISF)

A checklist standardizes site evaluation and ensures consistent practices across all clinical trial sites in compliance with USFDA and EMA guidelines.

Key Components of a Site Readiness Checklist

The checklist should be divided into the following categories, each encompassing critical startup elements:

1. Regulatory Documentation

• IRB/EC approval letter for protocol and ICF
• Signed and dated 1572 or country-specific equivalent
• GCP certificates for all site personnel
• Curricula vitae (CVs) of the PI and Sub-Is
• Delegation of Authority Log

2. Site Staff Training

• Protocol-specific training completed and documented
• System training (EDC, IWRS, ePRO) completed
• IP accountability and storage training provided

3. Investigational Product Management

• Temperature-controlled storage verified with backup monitoring
• Drug Accountability Logs available and prepared
• Unblinding procedures understood by PI
• Receipt of IP shipment documented

4. Equipment and Facility Readiness

• Calibrated equipment (centrifuges, ECG machines, etc.)
• Lab kits and sample processing supplies received
• Secure and locked storage for documents and IP
• Environmental controls in place and monitored

5. Site Personnel and Communication

• Staff roles and responsibilities clearly documented
• Contact list shared with sponsor and updated
• CRA and site staff communication plan agreed
• Escalation procedures defined

6. Source Documentation and ISF Review

• Source templates approved and filed
• Investigator Site File (ISF) organized with version control
• Pre-screening logs available (if applicable)
• Checklists signed by CRA and PI

Ensure that all components follow the relevant GMP documentation and Good Clinical Practice (GCP) principles.

Sample Site Readiness Checklist Template

1. ☐ IRB Approval Letter (Protocol and ICF)
2. ☐ Form 1572 Signed by PI
3. ☐ CV and GCP Certificate of PI and Sub-Is
4. ☐ Delegation of Authority Log Complete
5. ☐ Protocol and IP Training Completed
6. ☐ EDC/IWRS Training Complete
7. ☐ Drug Storage Conditions Verified
8. ☐ IP Accountability Records Available
9. ☐ All Site Equipment Calibrated and Documented
10. ☐ ISF Assembled and Reviewed
11. ☐ Site Contact List Confirmed
12. ☐ CRA/Monitor Communication Plan Finalized

Store this template in editable format at both the CRA and site end, and file a scanned signed version in the Trial Master File (TMF).

When to Use the Checklist

• Before and during the SIV to assess readiness
• After SIV as part of the activation approval process
• Before subject screening begins
• Prior to audits or inspections for readiness validation

Best Practices

1. Customize the checklist for study phase and therapeutic area
2. Review each checklist item with the site in real time
3. Use digital platforms for version control and signoff
4. Include a section for CRA observations and site action items
5. Cross-reference with Stability Studies templates for validation readiness

CRA Responsibilities

• Ensure checklist completion before site activation
• Flag missing items in the SIV Follow-Up Letter
• Verify all documents filed in ISF and TMF
• Obtain PI and CRA signatures on final checklist

Conclusion

A site readiness checklist is a cornerstone of clinical trial startup success. It enables CRAs and sponsors to ensure that nothing is overlooked and that each site meets all operational, regulatory, and protocol-specific requirements. By leveraging structured checklists, sponsors can reduce the risk of protocol deviations, site delays, and regulatory findings—ultimately ensuring a faster and safer path to study completion.

Site feasibility reviews are critical to identifying potential challenges before trial initiation. These assessments ensure that selected clinical trial sites possess the infrastructure, resources, and motivation to meet study requirements. However, sponsors and CROs often face difficulties when red flags are overlooked during this stage. This article outlines common warning signs during site feasibility reviews and offers guidance on how to address them to ensure successful site selection.

What is a Site Feasibility Review?

Site feasibility reviews evaluate a site’s suitability to conduct a specific clinical trial. These reviews gather data on infrastructure, staffing, patient population, and past performance. A comprehensive feasibility process helps sponsors minimize protocol deviations, recruitment failures, and regulatory issues.

The review may include feasibility questionnaires, telephone interviews, and pre-selection visits. When red flags are missed, costly delays and trial quality issues can arise.

Top Red Flags to Identify and Address:

1. Incomplete or Generic Feasibility Questionnaire Responses

• Missing data or vague answers in key sections like patient population, recruitment plans, or IRB timelines
• Responses that mirror template language without site-specific customization
• Contradictions between staff experience and protocol complexity

This often reflects a lack of engagement or familiarity with the protocol and should trigger a follow-up.

2. Limited Access to Target Patient Population

• Low patient numbers in the relevant indication over the past year
• Dependence on referrals without clear agreements or past success
• Limited access to databases for identifying eligible patients

This red flag suggests the site may struggle with enrollment timelines and retention goals.

3. High Staff Turnover or Resource Constraints

• Frequent changes in principal investigator (PI) or study coordinators
• Insufficient dedicated staff for clinical research tasks
• Part-time or overloaded study team members

Such sites may face issues with protocol adherence, data entry delays, and missed visits.

4. Weak Regulatory or Audit History

• Previous FDA or MHRA warning letters
• Repeated GCP violations or unresolved audit findings
• Poor record-keeping or protocol deviations

Always review the site’s compliance history and request any past audit reports.

5. Inadequate Infrastructure and Equipment

• Lack of temperature-controlled drug storage or uncalibrated equipment
• No backup systems for power, internet, or data access
• Shared research space with limited patient privacy

Such constraints affect drug accountability, data integrity, and patient comfort.

6. Overlapping Trials or Competing Commitments

• Multiple ongoing studies in the same therapeutic area
• Enrollment competition from similar protocols
• PI listed on too many active studies

Feasibility responses should account for site capacity and include realistic recruitment estimates.

7. Lack of Protocol Familiarity or PI Engagement

• PI is unavailable for feasibility calls or discussions
• Inability to answer basic protocol questions
• Reluctance to commit time for site qualification visits

Engaged investigators are vital for compliance and study success.

8. Delayed or Conditional Ethics Approval Process

• Sites that rely on external or infrequent IRB meetings
• Delays in past approval cycles for similar studies
• No clarity on local IRB submission process

Slow approval timelines can delay First Patient In (FPI) and project milestones.

How to Evaluate and Manage Red Flags:

1. Scoring and Documentation

Assign weighted scores to critical factors such as patient access, staffing, and PI experience. Document reasons for site disqualification or conditional approval.

2. Conduct Clarification Calls

If feasibility responses are ambiguous, schedule a feasibility interview with the PI and key staff. Clarify gaps and assess motivation firsthand.

3. Request Additional Documents

Ask for supplemental evidence such as past enrollment logs, site SOPs, and regulatory correspondence. This helps validate feasibility claims.

4. Use a Standardized Checklist

Standardized checklists aligned with Pharma SOP templates improve consistency across site assessments.

5. Consider Backup Sites

Always qualify a secondary list of sites to mitigate risks associated with high-risk or borderline locations.

Examples of Red Flag Scenarios:

Example 1: A site claims access to 100+ patients but cannot show any recruitment success for similar trials. This may indicate overestimation or marketing hype.

Example 2: A high-performing investigator is listed, but is also running five concurrent trials with limited support staff. The capacity to deliver quality data may be compromised.

Example 3: A rural hospital site lacks centrifuge equipment and contracts out lab work, causing delays in biosample shipments. This could pose problems for stability-sensitive samples requiring Stability Studies compliance.

Conclusion:

Identifying red flags early during the feasibility review phase is critical to clinical trial success. Whether it’s understaffing, infrastructure gaps, or regulatory weaknesses, each red flag provides insight into potential operational or compliance risks. Sponsors and CROs must combine structured tools, direct communication, and scoring systems to make data-driven site selection decisions. With a robust feasibility review process in place, study teams can minimize delays and ensure quality outcomes from the very start.